-
EP1187918
European procedure
Extract from the Register of European Patents
EP About this file: EP1187918
| EP1187918 - TEK ANTAGONISTS [Right-click to bookmark this link] | Status | Patent maintained as amended Status updated on 12.12.2008 Database last updated on 07.06.2024 | Most recent event Tooltip | 17.07.2009 | Correction of patent specification | published on 19.08.2009 [2009/34] | Applicant(s) | For all designated states Immunex Corporation One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US | [N/P] |
| Former [2006/16] | For all designated states IMMUNEX CORPORATION One Amgen Centre Drive Thousand Oaks, CA 91320-1799 / US | ||
| Former [2006/01] | For all designated states IMMUNEX CORPORATION One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US | ||
| Former [2005/25] | For all designated states Immunex Corporation Law Department, 51 University Street Seattle, WA 98101 / US | ||
| Former [2002/12] | For all designated states Immunex CorporatioN Law Department, 51 University Street Seattle, WA 98101 / US | Inventor(s) | 01 /
CERRETTI, Douglas, P. 1607 North 197th Place Seattle, WA 98133 / US | 02 /
BORGES, Luis, G. 3008 NW 57th Street Seattle, WA 98107 / US | 03 /
FANSLOW, William, C., III 404 SW 197th Street Normandy Park, WA 98166 / US | [2002/12] | Representative(s) | Cornish, Kristina Victoria Joy, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [N/P] |
| Former [2002/12] | Cornish, Kristina Victoria Joy, et al Kilburn & Strode, 20 Red Lion Street London WC1R 4PJ / GB | Application number, filing date | 00938207.8 | 07.06.2000 | [2002/12] | WO2000US15706 | Priority number, date | US19990137889P | 07.06.1999 Original published format: US 137889 P | [2002/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO0075323 | Date: | 14.12.2000 | Language: | EN | [2000/50] | Type: | A1 Application with search report | No.: | EP1187918 | Date: | 20.03.2002 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.12.2000 takes the place of the publication of the European patent application. | [2002/12] | Type: | B1 Patent specification | No.: | EP1187918 | Date: | 26.04.2006 | Language: | EN | [2006/17] | Type: | B2 New European patent specification | No.: | EP1187918 | Date: | 14.01.2009 | Language: | EN | [2009/03] | Type: | B9 Corrected patent specification | No.: | EP1187918 | Date: | 19.08.2009 | [2009/34] | Search report(s) | International search report - published on: | EP | 14.12.2000 | Classification | IPC: | C12N15/12, C07K14/71, G01N33/68, C07K19/00, C07K16/28, A61K38/17, A61K39/395 | [2002/12] | CPC: |
C07K14/71 (EP,US);
A61P27/02 (EP);
A61P35/00 (EP);
A61K38/00 (EP,US);
C07K2319/00 (EP,US);
C07K2319/02 (EP,US)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2002/12] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | TEK-ANTAGONISTEN | [2002/12] | English: | TEK ANTAGONISTS | [2002/12] | French: | ANTAGONISTES TEK | [2002/12] | Entry into regional phase | 04.01.2002 | National basic fee paid | 04.01.2002 | Designation fee(s) paid | 04.01.2002 | Examination fee paid | Examination procedure | 13.12.2000 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 04.01.2002 | Examination requested [2002/12] | 07.01.2002 | Amendment by applicant (claims and/or description) | 14.10.2002 | Despatch of a communication from the examining division (Time limit: M06) | 24.04.2003 | Reply to a communication from the examining division | 12.02.2004 | Despatch of a communication from the examining division (Time limit: M06) | 23.08.2004 | Reply to a communication from the examining division | 29.06.2005 | Date of oral proceedings | 27.07.2005 | Minutes of oral proceedings despatched | 29.08.2005 | Communication of intention to grant the patent | 22.12.2005 | Fee for grant paid | 22.12.2005 | Fee for publishing/printing paid | Opposition(s) | Opponent(s) | 01
26.01.2007
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE | [2007/10] | 15.03.2007 | Invitation to proprietor to file observations on the notice of opposition | 13.09.2007 | Reply of patent proprietor to notice(s) of opposition | 22.04.2008 | Date of oral proceedings | 15.05.2008 | Despatch of interlocutory decision in opposition | 15.05.2008 | Despatch of minutes of oral proceedings | 25.05.2008 | Legal effect of interlocutory decision in opposition | 01.09.2008 | Despatch of communication that the patent will be maintained as amended | 21.11.2008 | Fee for printing new specification paid | Fees paid | Renewal fee | 12.06.2002 | Renewal fee patent year 03 | 12.06.2003 | Renewal fee patent year 04 | 14.06.2004 | Renewal fee patent year 05 | 14.06.2005 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2007/45] |
| Former [2007/35] | IT | 26.04.2006 | Cited in | International search | [X]WO9400469 (IMMUNEX CORP [US]) [X] 8-10,12-17,19,43 * page 7 - page 8 * * page 18, line 34 - page 19, line 10 * * page 39 - page 41; claim - *; | [X]WO9513387 (MAX PLANCK GESELLSCHAFT [DE]) [X] 8-10,12,13,19,20,22,42 * page 6 * * page 14 - page 15 * * page 27 - page 29 * * page 57 - page 62; claim - *; | [X]WO9521866 (LUDWIG INST CANCER RES [US], et al) [X] 19,20,22,23,31-33,35,41-43* page 28 - page 29; claim - *; | [X]WO9611269 (REGENERON PHARMA [US], et al) [X] 8-10,12-16,19,20,22-29,31-33,35,41-43 * abstract * * page 8 - page 9 * * page 33 - page 36; example 2 * * page 54 - page 58; example 11 * * page 60 - page 67; claim - *; | [X]WO9631598 (REGENERON PHARMA [US], et al) [X] 8-10,12-16,19,20,22-29,31-33,35,41-43 * abstract * * page 8 * * page 39 - page 41; example 2 * * page 59 - page 61; example 11 * * page 70 - page 71; example 20 * * page 75 - page 84; claim - * |